Literature DB >> 23975724

Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status.

Nathan D Wong1, Christopher Patao, Kalina Wong, Shaista Malik, Stanley S Franklin, Uchenna Iloeje.   

Abstract

BACKGROUND: Most patients with type 2 diabetes mellitus (T2DM) suffer from cardiovascular disease (CVD). Whether CVD risk factors have improved in those with DM with and without CVD is not established. We compared risk factor levels and goal attainment in US adults with diabetes with and without CVD.
METHODS: We examined 2403 adults (aged ≥ 18 years) in the United States with T2DM (n = 654, 27% with CVD) across 1999-2010 using the US National Health and Nutrition Examination Survey (NHANES) and evaluated control of hemoglobin A1c (HbA1c), blood pressure (BP), low-density lipoprotein cholesterol (LDL-C) and body mass index (BMI) in those with DM with versus without CVD.
RESULTS: The proportions controlled for HbA1c, BP and LDL-C have improved (p < 0.001) overall between 1999 and 2010, but only 24% were at goal for all three factors in 2009-2010. There were improvements in BP, triglycerides and LDL-C in those with CVD, and in those without CVD, there were also improvements in control of all parameters, although changes in mean levels of risk factors were less impressive.
CONCLUSION: Despite modest improvement over time, in most CVD risk factors, only one-fourth of those with T2DM are at goal for HbA1c, BP and LDL-C, with improvements seen in those without CVD more often than those with CVD.

Entities:  

Keywords:  Diabetes; cardiovascular disease; risk factors; trends

Mesh:

Substances:

Year:  2013        PMID: 23975724      PMCID: PMC4227398          DOI: 10.1177/1479164113496828

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  21 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 3.  Impact of weight gain on outcomes in type 2 diabetes.

Authors:  Stuart A Ross; Grzegorz Dzida; Jiten Vora; Kamlesh Khunti; Marcel Kaiser; Robert J Ligthelm
Journal:  Curr Med Res Opin       Date:  2011-05-23       Impact factor: 2.580

Review 4.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.

Authors:  Amit Sachdeva; Christopher P Cannon; Prakash C Deedwania; Kenneth A Labresh; Sidney C Smith; David Dai; Adrian Hernandez; Gregg C Fonarow
Journal:  Am Heart J       Date:  2008-10-22       Impact factor: 4.749

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 10.  Economic costs of diabetes in the U.S. In 2007.

Authors: 
Journal:  Diabetes Care       Date:  2008-03       Impact factor: 19.112

View more
  31 in total

1.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

Review 2.  The Framingham Heart Study--67 years of discovery in metabolic disease.

Authors:  Michelle T Long; Caroline S Fox
Journal:  Nat Rev Endocrinol       Date:  2016-01-18       Impact factor: 43.330

Review 3.  Type 2 diabetes and cardiovascular disease: what next?

Authors:  Joshua J Joseph; Sherita Hill Golden
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-04       Impact factor: 3.243

Review 4.  The emergence of cardiodiabetology.

Authors:  Paul D Rosenblit; Norman E Lepor; Nathan D Wong
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

5.  Cardiodiabetology: The convergence of diabetes and cardiovascular disease.

Authors:  Nathan D Wong
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

Review 6.  Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome.

Authors:  Robert E Heinl; Devinder S Dhindsa; Elliot N Mahlof; William M Schultz; Johnathan C Ricketts; Tina Varghese; Amirhossein Esmaeeli; Marc P Allard-Ratick; Anthony J Millard; Heval M Kelli; Pratik B Sandesara; Danny J Eapen; Laurence Sperling
Journal:  Can J Cardiol       Date:  2016-07-22       Impact factor: 5.223

7.  Design and participant characteristics for a randomized effectiveness trial of an intensive lifestyle intervention to reduce cardiovascular risk in adults with type 2 diabetes: The I-D-HEALTH study.

Authors:  David T Liss; Emily A Finch; Dyanna L Gregory; Andrew Cooper; Ronald T Ackermann
Journal:  Contemp Clin Trials       Date:  2015-12-02       Impact factor: 2.226

8.  Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study.

Authors:  Nathan D Wong; Yanglu Zhao; Rohini Patel; Christopher Patao; Shaista Malik; Alain G Bertoni; Adolfo Correa; Aaron R Folsom; Sumesh Kachroo; Jayanti Mukherjee; Herman Taylor; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2016-03-29       Impact factor: 19.112

9.  Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry.

Authors:  Angela Lowenstern; Shuang Li; Salim S Virani; Ann Marie Navar; Zhuokai Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Andrew Koren; Michael J Louie; Eric D Peterson; Tracy Y Wang
Journal:  Am Heart J       Date:  2020-04-30       Impact factor: 4.749

10.  Comorbid hypertension and diabetes among U.S. women of reproductive age: Prevalence and disparities.

Authors:  Laura E Britton; Diane C Berry; Jon M Hussey
Journal:  J Diabetes Complications       Date:  2018-09-26       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.